CAMP4 Therapeutics Corporation announced its financial results for the second quarter ended June 30, 2025, along with corporate highlights. The company reported cash, cash equivalents, and marketable securities of $39.1 million as of June 30, 2025, a decrease from $49.3 million at March 31, 2025.
Research and development expenses for the quarter were $10.3 million, an increase from $9.4 million in Q2 2024, primarily driven by increased clinical and preclinical study costs. General and administrative expenses rose to $4.2 million from $3.3 million in the prior-year quarter. The net loss for the quarter was $12.6 million, consistent with $12.6 million in Q2 2024.
The company presented compelling translational data from its SYNGAP1 program, reinforcing confidence in CMP-SYNGAP-01's potential. CAMP4 is on track to initiate GLP toxicology studies in the third quarter of 2025, which could support the initiation of a global Phase 1/2 clinical trial in SYNGAP patients in the second half of 2026. For CMP-CPS-001, the lead candidate for Urea Cycle Disorders, safety and biomarker data from the Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) portions of the ongoing Phase 1 trial in healthy volunteers are expected in Q4 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.